NCT06959615View on ClinicalTrials.gov

A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

334

Participants

Timeline

Start Date

November 22, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

August 31, 2027

Conditions
Advanced Solid Tumor
Interventions
DRUG

JAB-23E73

Administered orally

DRUG

JAB-23E73

Administered orally

Trial Locations (4)

100021

RECRUITING

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

100032

RECRUITING

Peking Union Medical College Hospital, Beijing

310005

NOT_YET_RECRUITING

Zhejiang Cancer Hospital, Hangzhou

650118

RECRUITING

ShanXi Cancer Hospital, Taiyuan

Sponsors
All Listed Sponsors
lead

Jacobio Pharmaceuticals Co., Ltd.

INDUSTRY